Tracer library / [177Lu]Lu-CE-21
[177Lu]Lu-CE-21
Also written as [Lu-177]Lu-CE-21
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Clinical research
- Syntheses indexed
- 0
What it is
- Compound class
- Anti-CEA nanobody (single-domain antibody) conjugate
- Target / mechanism
- Targets carcinoembryonic antigen (CEA) PMID 41275230
- Clinical application
- CEA-targeted theranostic platform combining PET imaging with radionuclide therapy in oncology PMID 41275230
- Theranostic pair
- [68Ga]CE-21
Published syntheses
No synthesis has been parsed for this agent yet.
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
- A high-affinity CEA-targeted nanobody for 68Ga PET imaging and 177Lu-based radioisotope therapy: preclinical and first-in-human evaluation.2025 · J Nanobiotechnology · Clinical study
Need this precursor?We can point you to suppliers for [177Lu]Lu-CE-21, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 41275230. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41275230: 'CEA-Nanobody (CE-21-NOTA conjugate)'. Stage set/updated at stage 23 from PMID 41275230: 'A high-affinity CEA-targeted nanobody for 68Ga PET imaging and 177Lu-based radioisotope therapy: preclinical and first-in-human evaluation.'. | Stage 30 (2026-09-18): Stage was 'first-in-human'; normalised to 'Clinical research', original wording kept here.